A number of osteocyte-related biomarkers have been used to predict the incidence of CKD–MBD, including sclerostin, Dickkopf-1 (DDK1), fibroblast growth factor 23 (FGF23), bone-specific alkaline, procollagen type 1 N-terminal propeptide, osteocalcin, procollagen type 1 C-terminal propeptide, hydroxyp roline, hydroxylysine, deoxypyridinoline, pyridinoline, bone sialoprotein, osteopontin, tartrate-resistant acid phosphatase 5b, receptor activator of NF-kB ligand and osteoprotegerin [4,5]. This evidence concerns the gene FGF23 and Marchiafava-Bignami disease.